Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

Hallucinations in Parkinson's disease are common, can complicate medication management and significantly impact upon the quality of life of patients and their carers. This review aims to examine current evidence for the management of hallucinations in Parkinson's disease. Treatment of hallucinations in Parkinson's disease should be both individualized and multifaceted. Screening, education, medication review and the avoidance of common triggers are important. For well-formed visual hallucinations, acetylcholinesterase inhibitors are recommended first-line. Refractory or severe symptoms may require the cautious use of atypical antipsychotics. Antidepressants may be beneficial in the appropriate setting. Unfortunately, current therapies for hallucinations offer only limited benefits and future research efforts are desperately required to improve the management of these challenging symptoms.


Alice Powell, Elie Matar, Simon J G Lewis. Treating hallucinations in Parkinson's disease. Expert review of neurotherapeutics. 2022 Jun;22(6):455-468

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 33183105

View Full Text